Chardan Capital Reiterates “Buy” Rating for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $1.25 price objective on the biotechnology company’s stock. Chardan Capital’s target price would suggest a potential upside of 111.11% from the company’s current price.

MCRB has been the subject of several other research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Friday, September 13th. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

NASDAQ:MCRB opened at $0.59 on Wednesday. The stock’s fifty day moving average price is $0.86 and its two-hundred day moving average price is $0.92. The company has a market cap of $100.78 million, a P/E ratio of -0.50 and a beta of 2.06. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.08. During the same quarter in the previous year, the firm posted $0.36 EPS. On average, analysts expect that Seres Therapeutics will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Providence Wealth Advisors LLC boosted its holdings in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Seres Therapeutics in the 1st quarter worth approximately $39,000. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $64,000. Virtu Financial LLC purchased a new position in shares of Seres Therapeutics during the first quarter valued at approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Seres Therapeutics during the second quarter valued at approximately $92,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.